Micafungin Pharmore

Micafungin, the active ingredient in Micafungin Pharmore, is an Echinocandin presented as an intravenous formulation for infusion use. It treats serious fungal infections such as invasive candidiasis and esophageal candidiasis, and is used for prophylaxis in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Pharmore as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product meets European market standards and is manufactured under strict quality controls.

Micafungin is an antifungal agent indicated for several Candida‑related conditions.

Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. Esophageal candidiasis: resolves mucosal infection and associated symptoms. Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during the high‑risk post‑transplant period.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion‑related reactions: flushing, erythema, or pruritus at the infusion site. - Gastrointestinal disturbances: nausea, vomiting, or abdominal pain. - Elevated liver enzymes: transient increase in ALT or AST. - Fever: mild to moderate temperature rise.

Serious or Rare Side Effects: - Hypersensitivity reactions: anaphylaxis, angioedema, or severe rash. - Hepatotoxicity: marked elevation of liver transaminases or bilirubin. - Renal impairment: acute kidney injury or increased serum creatinine. - Severe neutropenia: marked reduction in white blood cell count.

When using Micafungin, clinicians should observe several safety considerations.

Renal function: monitor serum creatinine and urine output during therapy. Hepatic function: check liver enzymes before and periodically during treatment. Infusion reactions: be prepared to manage hypotension, rash, or bronchospasm. Concomitant nephrotoxic agents: use with caution and adjust dosing if needed. Pregnancy and lactation: avoid unless benefit outweighs potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Micafungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin exposure. - Azole antifungals (e.g., fluconazole, itraconazole): may increase micafungin levels and risk of toxicity. - Immunosuppressants (e.g., tacrolimus, cyclosporine): may raise drug concentrations, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., phenobarbital): may lower micafungin concentrations. - Warfarin: monitor INR as micafungin may affect anticoagulant effect. - Concurrent use of other antifungals: assess for additive toxicity.